YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
105 hedge funds and large institutions have $339M invested in Y-mAbs Therapeutics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
105
Holders Change
+10
Holders Change %
+10.53%
% of All Funds
1.52%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.01%
New
19
Increased
38
Reduced
28
Closed
9
Calls
$563K
Puts
$5K
Net Calls
+$558K
Net Calls Change
+$233K
Top Buyers
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.5M |
| 2 |
CP
Caligan Partners
New York
|
+$8.06M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.33M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.84M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$2.47M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$3.66M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.47M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.26M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.85M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.83M |
